MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage numerous intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Primary demo objectives were to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyositis patients, although one of the explorato... https://salmeterolxinafoate25679.blog-ezine.com/31035243/detailed-notes-on-m3541